Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) is among the many 11 Finest GLP-1 and Weight Loss Shares to Spend money on. Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) awarded the thirteenth annual Regeneron Prize for Artistic Innovation to early-career biomedical researchers who displayed distinctive innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar Mantena, a Harvard-MIT M.D.-Ph.D. candidate and Broad Institute nominee. Every obtained an institutional award of $5,000 and $50,000.
Copyright: delcreations / 123RF Inventory Photograph
Prime U.S. analysis establishments nominate candidates for the Regeneron Prize to submit “dream tasks” in biomedicine. Dr. Hillis from Professor Matthew Vander Heiden’s lab advised new strategies for researching endometriosis. Mr. Mantena, who works underneath Professor Soumya Raychaudhuri at Brigham and Ladies’s Hospital, needs to research thymic lower with age utilizing single-cell genomics. Seven different finalists earned $5,000 every. The prize has given out near $2 million because it was established in 2013. Regeneron Prescribed drugs, Inc. (NASDAQ:REGN)’s broader STEM packages have reached 3.25 million college students worldwide since 2020.
Whereas we acknowledge the potential of REGN as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back threat. In case you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Excessive-Progress EV Shares to Make investments In and 13 Finest Automotive Shares to Purchase in 2025.
Disclosure. None.
Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) is among the many 11 Finest GLP-1 and Weight Loss Shares to Spend money on. Regeneron Prescribed drugs, Inc. (NASDAQ:REGN) awarded the thirteenth annual Regeneron Prize for Artistic Innovation to early-career biomedical researchers who displayed distinctive innovation. The winners for 2025 are Dr. Alissandra L. Hillis, a postdoctoral fellow at MIT, and Mr. Sreekar Mantena, a Harvard-MIT M.D.-Ph.D. candidate and Broad Institute nominee. Every obtained an institutional award of $5,000 and $50,000.
Copyright: delcreations / 123RF Inventory Photograph
Prime U.S. analysis establishments nominate candidates for the Regeneron Prize to submit “dream tasks” in biomedicine. Dr. Hillis from Professor Matthew Vander Heiden’s lab advised new strategies for researching endometriosis. Mr. Mantena, who works underneath Professor Soumya Raychaudhuri at Brigham and Ladies’s Hospital, needs to research thymic lower with age utilizing single-cell genomics. Seven different finalists earned $5,000 every. The prize has given out near $2 million because it was established in 2013. Regeneron Prescribed drugs, Inc. (NASDAQ:REGN)’s broader STEM packages have reached 3.25 million college students worldwide since 2020.
Whereas we acknowledge the potential of REGN as an funding, we consider sure AI shares supply larger upside potential and carry much less draw back threat. In case you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the finest short-term AI inventory.
READ NEXT: 10 Excessive-Progress EV Shares to Make investments In and 13 Finest Automotive Shares to Purchase in 2025.
Disclosure. None.
